Phase I-II Trial of the Anti CD74 Monoclonal Antibody-Milatuzumab as a Single Agent in Refractory Chronic Lymphocytic Leukemia.
Phase of Trial: Phase I/II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Milatuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 04 Sep 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 07 Apr 2009 New trial record